Aspira Pathlab & Diagnostics Ltd.
BSE: 540788
₹117.60
₹0.00 (0.00%)As on 16-Jun-2026IST
Market cap
₹121 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
2327.8
P/B Ratio
9.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹0 Cr
-
ROE
18.1 %
-
ROCE
19.3 %
-
Industry P/E
3,559.77
-
EV/EBITDA
61
-
Debt to Equity
0.1
-
Book Value
₹11.9
-
EPS
₹0.1
-
Face value
10
-
Shares outstanding
10,293,000
10 Years Aggregate
CFO
₹-1.15 Cr
EBITDA
₹2.00 Cr
Net Profit
₹-12.60 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aspira Pathlab
| 77.7 | 29.2 | 95.5 | 94.6 | 56.8 | -- | -- |
|
BSE Healthcare
| 8.3 | -0.3 | 9.9 | 6.9 | 23.6 | 13.2 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Aspira Pathlab
| 9.0 | 52.6 | -9.0 | -44.2 | 180.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aspira Pathlab
|
117.6 | 121.1 | 25.0 | 0.1 | -0.3 | 0.4 | 2327.8 | 9.9 |
| 780.1 | 40,395.3 | 4,643.2 | 464.1 | 13.7 | 8.9 | 104.1 | 8.8 | |
| 8.7 | 7.5 | 4.5 | 0.4 | -- | 4.3 | 118.9 | 0.5 | |
| 1,642.0 | 27,501.8 | 2,762.9 | 509.8 | 22.5 | 21.5 | 54.5 | 11.0 | |
| 10.5 | 11.0 | 0.0 | -1.7 | -- | -7.2 | -- | 0.5 | |
| 778.7 | 31,136.8 | 3,904.6 | 239.4 | 13.3 | 11.1 | 129 | 13.9 | |
| 139.9 | 291.0 | 53.7 | 0.1 | -0.7 | 0.1 | 3593.1 | 4.8 | |
| 115.0 | 38.5 | 16.4 | 1.7 | 7.3 | 4.8 | 22.2 | 1.1 | |
| 15.3 | 34.8 | 0.0 | -8.7 | -48,411.1 | -66.4 | -- | 3.0 | |
| 72.6 | 31.0 | 26.3 | -2.7 | -5.4 | -- | -- | -22.0 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Aspira Pathlab
Hospital activities
-
Incorporated
1973
-
Chairman
Haseeb A Drabu
-
Managing Director
Pankaj Shah
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsIntegrated Financial Results As On March 31 2026
23-May-2026No News & Announcements are available.
FAQs for Aspira Pathlab
What is the current share price of Aspira Pathlab & Diagnostics Ltd Today?
The share price of Aspira Pathlab & Diagnostics Ltd is ₹117.60 (BSE) as of 16-Jun-2026 IST. Aspira Pathlab & Diagnostics Ltd has given a return of 56.83% in the last 3 years.
What is the current PB & PE ratio of Aspira Pathlab & Diagnostics Ltd?
Since, TTM earnings of Aspira Pathlab & Diagnostics Ltd is negative, P/E ratio is not available.
The P/B ratio of Aspira Pathlab & Diagnostics Ltd is 9.90 times as on 16-Jun-2026, a 231 premium to its peers’ median range of 2.99 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
43.37
|
7.21
|
|
2024
|
0.00
|
3.15
|
|
2023
|
0.00
|
2.25
|
|
2022
|
14.96
|
5.22
|
|
2021
|
21.24
|
3.53
|
What is the 52 Week High and Low of Aspira Pathlab & Diagnostics Ltd?
The 52-week high and low of Aspira Pathlab & Diagnostics Ltd are Rs 135.88 and Rs 49.00 as of 16-Jun-2026.
What is the market cap of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd has a market capitalisation of ₹ 121 Cr as on 16-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aspira Pathlab & Diagnostics Ltd?
Before investing in Aspira Pathlab & Diagnostics Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.